Skip to content
AdFinancial Legend: “This Is Bad, Really Bad...”

Articles

UnitedHealth (UNH) Falls 10% as CMS Targets Medicare Advantage Audits

Nov 19, 2026 · Trading Tips

UnitedHealth (UNH) has lost real ground in two sessions, and the trigger is a proposed federal rule that hasn't even been finalized.

The stock fell 10.2% Wednesday to close at $349.91, after dropping 5.4% Tuesday. The Dow took the hit: UnitedHealth carries about a 4.3% weighting in the index, which finished down 1.1%.

The pain spread across Medicare Advantage insurers. Per StockAnalysis, Humana (HUM) fell 13.0%, Elevance Health (ELV) lost 7.6%, CVS Health (CVS) dropped 5.2% and Cigna (CI) slipped 3.0%.

The catalyst is a Centers for Medicare & Medicaid Services proposal called CRUSH, short for Comprehensive Regulations to Uncover Suspicious Healthcare. CMS says the rule targets fraud across Medicare, Medicaid, CHIP and the ACA marketplace and could save taxpayers nearly $90 billion over 10 years.

The part that matters for insurers is about audits. Medicare Advantage plans get paid more for sicker members, and CMS audits sample medical records to check the diagnoses. Under the proposal, CMS would extrapolate what a sample finds across a plan's wider payments, starting with payment year 2018. CMS estimates that would recover about $9 billion per payment year.

"We believe CMS will be subject to the same legal challenges that it faced in 2025." — Oppenheimer analysts

That's from Oppenheimer, quoted in Yahoo Finance's coverage. A federal court struck down a comparable framework in 2025. The firm also noted that recoveries would be concentrated in 2028 through 2030, and that if the rule survives, insurers would likely build the added cost into future plan bids rather than eat it in earnings.

Exposure is the issue for UnitedHealth specifically. It's the biggest Medicare Advantage insurer, and CMS premiums made up 44% of its 2025 revenue, as Yahoo Finance's TIKR analysis noted. The company hasn't said how much of the $9 billion-a-year estimate would be its share.

The cushion is thin. UnitedHealth's operating margin fell to 4.8% in 2025 from 8.1% in 2024, and analysts were counting on a recovery, with normalized EPS expected to climb from $16.35 in 2025 to $23.33 in 2027. Those estimates predate this proposal. Any repayment, or even a reserve, would come out of that narrower margin.

Valuation offers some help but not much. After Tuesday's drop the stock traded around 17 times forward earnings, below its five-year average of 19. Wednesday's slide pushed it lower still. That's a fair discount for a bill nobody has sized. It isn't enough if the bill is large.

Humana looks more fragile. TIKR's analysis put it at roughly 27 times forward earnings before this week's drop, with 2026 adjusted EPS guided to at least $9.50 and Street hopes of $18.45 for 2027. A rebound that steep leaves little room for a clawback.

Don't assume the worst is baked in or that it's guaranteed. This is a proposed rule. CMS accepts public comments until January 19, 2027, and can change the text before finalizing. Litigation could delay it or kill it, as it did the earlier framework.

The next real checkpoint for UNH holders is the 2027 outlook, which management has promised before year-end. A guide at or above the $23.33 consensus, plus some word on audit exposure, would go a long way toward steadying the stock. A cut, or silence on the audits, would do the opposite.

For anyone watching the sector, also keep an eye on the comment period and any signs the administration is softening the extrapolation language. Cigna fell only 3% on Wednesday against double-digit drops for UnitedHealth and Humana, a reminder that this selloff is about exposure to Medicare Advantage audits.

Bottom line: the selloff prices in a legal and financial fight that's years from resolution, so expect volatility until UnitedHealth sizes its exposure.